Platensimycin
Platensimycin structure
|
Common Name | Platensimycin | ||
|---|---|---|---|---|
| CAS Number | 835876-32-9 | Molecular Weight | 441.474 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 683.1±55.0 °C at 760 mmHg | |
| Molecular Formula | C24H27NO7 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 366.9±31.5 °C | |
Use of PlatensimycinPlatensimycin is an antibiotic produced by S. platensis that inhibits gram-positive bacteria by selectively inhibiting cellular lipid biosynthesis (IC50=0.1 μM). Platensimycin targets the β-ketoacyl-acyl-carrier-protein synthase I/II, FabF/B, an enzyme that participates in the biosynthesis of fatty acids (IC50s=48 nM and 160 nM for S.aureus and E.coli enzymes, respectively). Platensimycin is a promising agent for overcoming antibiotic resistance. |
| Name | platensimycin |
|---|---|
| Synonym | More Synonyms |
| Description | Platensimycin is an antibiotic produced by S. platensis that inhibits gram-positive bacteria by selectively inhibiting cellular lipid biosynthesis (IC50=0.1 μM). Platensimycin targets the β-ketoacyl-acyl-carrier-protein synthase I/II, FabF/B, an enzyme that participates in the biosynthesis of fatty acids (IC50s=48 nM and 160 nM for S.aureus and E.coli enzymes, respectively). Platensimycin is a promising agent for overcoming antibiotic resistance. |
|---|---|
| Related Catalog |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 683.1±55.0 °C at 760 mmHg |
| Molecular Formula | C24H27NO7 |
| Molecular Weight | 441.474 |
| Flash Point | 366.9±31.5 °C |
| Exact Mass | 441.178741 |
| PSA | 136.65000 |
| LogP | 3.00 |
| Vapour Pressure | 0.0±2.2 mmHg at 25°C |
| Index of Refraction | 1.670 |
| InChIKey | CSOMAHTTWTVBFL-OFBLZTNGSA-N |
| SMILES | CC12CC34C=CC(=O)C(C)(CCC(=O)Nc5c(O)ccc(C(=O)O)c5O)C3C(CC1C4)O2 |
| RIDADR | NONH for all modes of transport |
|---|
|
FabH mutations confer resistance to FabF-directed antibiotics in Staphylococcus aureus.
Antimicrob. Agents Chemother. 59(2) , 849-58, (2015) Delineating the mechanisms for genetically acquired antibiotic resistance is a robust approach to target validation and anticipates the evolution of clinical drug resistance. This study defines a spec... |
|
|
Acyl-CoA synthetase 3 promotes lipid droplet biogenesis in ER microdomains.
J. Cell Biol. 203(6) , 985-1001, (2013) Control of lipid droplet (LD) nucleation and copy number are critical, yet poorly understood, processes. We use model peptides that shift from the endoplasmic reticulum (ER) to LDs in response to fatt... |
|
|
Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes.
Proc. Natl. Acad. Sci. U. S. A. 108 , 5378-5383, (2011) Platensimycin (PTM) is a recently discovered broad-spectrum antibiotic produced by Streptomyces platensis. It acts by selectively inhibiting the elongation-condensing enzyme FabF of the fatty acid bio... |
| 3-({3-[(1S,4aS,6S,7S,9S,9aR)-1,6-dimethyl-2-oxo-1,2,5,6,7,8,9,9a-octahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid |
| Platensimycin |
| 3-({3-[(1S,5S,6R,7S,9S,10S)-5,9-Dimethyl-4-oxo-8-oxatetracyclo[7.2.1.1.0]tridec-2-en-5-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid |